AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02094053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (oral) once daily, for 24 weeks
Study NCT04343209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myocardial Perfusion Imaging Study
Description: Evaluation of myocardial perfusion via PET imaging agent
Study NCT04343209 — intervention group
Intervention type: DRUG
Intervention: AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]
Description: Cardiac PET imaging agent
Study NCT04268472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP30101
Description: Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
Study NCT04268472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prezista®
Description: Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
Study NCT01093001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echo
Description: Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
Study NCT01093001 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Echo
Description: Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Study NCT00862238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Promotion
Description: 4 session education which offers basic information about the prevention of hepatitis A, B, \& C
Study NCT04660890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: ALXN2050 will be administered orally twice daily as powder-in-capsule.
Study NCT04660890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALXN2050-matching Placebo
Description: ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
Study NCT04660890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be administered as a single oral dose.
Study NCT04660890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin-matching Placebo
Description: Moxifloxacin-matching placebo will be administered as a single oral dose.
Study NCT04660890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching Placebo
Description: Moxifloxacin-matching placebo will be administered as a single oral dose.
Study NCT03842735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and rehabilitation counselling
Description: The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
Study NCT03842735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation counselling
Description: RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
Study NCT03842735 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: rehabilitation counselling
Description: RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
Study NCT05361460 — intervention group
Intervention type: OTHER
Intervention: Cognitive decline
Description: This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
Study NCT02398812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication assessment and treatment plan based on it
Description: Intervention~* Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~* Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician.
Study NCT02239926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
Study NCT02239926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02704208 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Thrive With Me Control
Description: Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
Study NCT02704208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive With Me Intervention
Description: Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
Study NCT04212663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The tendon release of musculi tibialis posterior
Description: To release the tendon of musculi tibialis posterior.
Study NCT04212663 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Anterior tibial tendon transfer(TATT)
Description: To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.
Study NCT04212663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior tibial tendon transfer(TATT)
Description: To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.
Study NCT04212663 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Achilles tendon lengthing
Description: To lengthen the achilles tendon by using two incisions.
Study NCT04212663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Achilles tendon lengthing
Description: To lengthen the achilles tendon by using two incisions.
Study NCT04212663 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fascial release
Description: To cut off the metatarsal fascia in the middle part.
Study NCT04212663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascial release
Description: To cut off the metatarsal fascia in the middle part.
Study NCT01652781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
Study NCT01652781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
Study NCT03590886 — intervention group
Intervention type: OTHER
Intervention: total response Group
Description: biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
Study NCT01041430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: day surgery group
Description: inguinal hernia repair, discharge from the hospital on the day of surgery
Study NCT01041430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inpatient group
Description: inguinal hernia repair, patient admitted overnight to hospital
Study NCT01528579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck Specific Exercises
Description: 2 times a week for 3 months followed by encourages to continue on their own
Study NCT01528579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral approach combined with neck specific exercises
Description: Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
Study NCT01528579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed Physical activity
Description: Physical activity without neck specific exercises for 3 months
Study NCT01561833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
Study NCT05749471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ASEX (Arizona Sexual Experience) administration
Description: ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of > 19, any one item with a score of > 5, or any three items with a score of > 4 would have sexual dysfunction.
Study NCT03917030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement with osteoplasty
Description: Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the toot.
Study NCT03917030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement with osteoplasty
Description: Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the toot.
Study NCT03917030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement without osteoplasty
Description: Treatment of furcation grade II defect with open flap debridement only.
Study NCT03917030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement without osteoplasty
Description: Treatment of furcation grade II defect with open flap debridement only.
Study NCT02121509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: 1 x Linagliptin tablet
Study NCT02121509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin ER FDC
Description: 2 x Linagliptin/Metformin ER FDC tablet
Study NCT02121509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: 3 x Metformin ER tablets
Study NCT03493958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Description: The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face cognitive behavioral therapy for insomnia (CBT-I) components including sleep restriction, stimulus control, sleep hygiene, cognition
Study NCT00586794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 3x per day 20 mg TID
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranylcypromine
Study NCT01896349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranylcypromine
Study NCT00586794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x per day, 20 mg TID
Study NCT00815386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous transvenous mitral annuloplasty
Description: Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
Study NCT02367963 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training period
Description: Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
Study NCT02367963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training period
Description: Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
Study NCT02367963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-group
Description: The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
Study NCT04817202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, single dose)
Description: Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)
Study NCT04817202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (subcutaneous, single dose)
Description: Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
Study NCT04817202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hzVSF-v13 (intravenous, multiple dose)
Description: Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
Study NCT00560781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone or Placebo
Description: Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
Study NCT00560781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregnenolone or Placebo
Description: Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
Study NCT04817202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (intravenous, single dose)
Description: Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)
Study NCT04817202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (subcutaneous, single dose)
Description: Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
Study NCT04817202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (intravenous, multiple dose)
Description: Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
Study NCT03978832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERSERIS
Description: PERSERIS is an extended-release SC injectable suspension administered once-monthly
Study NCT00706147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimoclomol
Description: Drug: Arimoclomol capsules given three times per day
Study NCT00706147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo capsules given three times per day
Study NCT02554994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifactorial intervention
Description: There are six components of intervention in this study.~* For all participants:~  1. Group exercise~ 2. Nutritional supplement(commercial liquid formula will be provided every day).~* For selected participants:~  1. Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~ 2. At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~ 3. Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it).
Study NCT02554994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS).
Study NCT01615783 — intervention group
Intervention type: OTHER
Intervention: Subjects with COPD
Description: Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
Study NCT01615783 — intervention group
Intervention type: OTHER
Intervention: Subjects without COPD
Description: Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
Study NCT02315092 — intervention group
Intervention type: DEVICE
Intervention: Fluorescence Imaging
Description: Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
Study NCT01069913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BG00012
Description: Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation.
Study NCT01453166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brazilian heart-prevent meal
Description: Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
Study NCT01453166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart prevent control meal weekly
Description: received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions